Advances in therapeutic strategies for the treatment of pruritus

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 5, 2016, Pages 671-687

  Stull, Carolyn ^a   Lavery, Michael J ^a   Yosipovitch, Gil ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antipruritics; Atopic dermatitis; autotaxin; biologics; chronic pruritus; IL 31; nerve growth factor; neural hypersensitization; neuropeptides; nonhistaminergic itch; psoriasis

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIPRURITIC AGENT; CANNABINOID; CORTICOSTEROID; IMMUNOGLOBULIN E ANTAGONIST; IMMUNOMODULATING AGENT; INTERLEUKIN 12 ANTAGONIST; INTERLEUKIN 13 ANTAGONIST; INTERLEUKIN 17 ANTAGONIST; INTERLEUKIN 23 ANTAGONIST; INTERLEUKIN 31 ANTAGONIST; INTERLEUKIN 4 ANTAGONIST; ION CHANNEL INHIBITOR; NEUROKININ 1 RECEPTOR ANTAGONIST; OPIATE AGONIST; OPIATE ANTAGONIST; PHOSPHODIESTERASE IV INHIBITOR; PROSTANOID AGONIST; PROSTANOID INHIBITOR; PROTEIN TYROSINE KINASE A INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; STRONTIUM; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1 ANTAGONIST; TRANSIENT RECEPTOR POTENTIAL CHANNEL AFFECTING AGENT; TRANSIENT RECEPTOR POTENTIAL CHANNEL AGONIST; TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 3 ANTAGONIST;

CORTICOSTEROID THERAPY; HUMAN; NONHUMAN; OAT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; TOPICAL TREATMENT; CHRONIC DISEASE; TREATMENT OUTCOME;

ANTIPRURITICS; CHRONIC DISEASE; HUMANS; PRURITUS; TREATMENT OUTCOME;

EID: 84951272702     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1127355     Document Type: Review

References (146)

1. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2015 May 1. [Epub ahead of print].
2. Stander S, Weisshaar E, Mettang T, et al. Clinical classification of itch: A position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87(4):291-294.
3. Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol. 2009;89(4):339-350.
4. Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch. Handb Exp Pharmacol. 2015;226:337-356.
5. Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatolog Treat. 2009;20(2):76-81.
6. Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother. 2010;11(10):1673-1682.
7. Valdes-Rodriguez R, Kaushik SB, Yosipovitch G. Transient receptor potential channels and dermatological disorders. Curr Top Med Chem. 2013;13(3):335-343.
8. Papoiu AD, Chaudhry H, Hayes EC, et al. TriCalm((R)) hydrogel is significantly superior to 2% diphenhydramine and 1% hydrocortisone in reducing the peak intensity, duration, and overall magnitude of cowhage-induced itch. Clin Cosmet Investig Dermatol. 2015;8:223-229.
9. Eberlein B, Eicke C, Reinhardt HW, et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008;22(1):73-82.
10. Kurtz ES, Wallo W. Colloidal oatmeal: history, chemistry and clinical properties. J Drugs Dermatol. 2007;6(2):167-170.
11. Griffin JR, Davis MD. Amitriptyline/ketamine as therapy for neuropathic pruritus and pain secondary to herpes zoster. J Drugs Dermatol. 2015;14(2):115-118.
12. Poterucha TJ, Murphy SL, Davis MD, et al. Topical amitriptyline-ketamine for the treatment of brachioradial pruritus. JAMA Dermatol. 2013;149(2):148-150.
13. Poterucha TJ, Murphy SL, Sandroni P, et al. Topical amitriptyline combined with topical ketamine for the management of recalcitrant localized pruritus: A retrospective pilot study. J Am Acad Dermatol. 2013;69 (2):320-321.
14. Kircik LH. Efficacy and onset of action of hydrocortisone acetate 2.5% and pramoxine hydrochloride 1% lotion for the management of pruritus: results of a pilot study. J Clin Aesthet Dermatol. 2011;4(2):48-50.
15. Misery L, Erfan N, Castela E, et al. Successful treatment of refractory neuropathic pruritus with capsaicin 8% patch: a bicentric retrospective study with long-term follow-up. Acta Derm Venereol. 2015;5(7):864-865.
16. Yosipovitch G, Sugeng MW, Chan YH, et al. The effect of topically applied aspirin on localized circumscribed neurodermatitis. J Am Acad Dermatol. 2001;45(6):910-913.
17. Yosipovitch G, Bernhard JD. Clinical practice. chronic pruritus. N Engl J Med. 2013;368(17):1625-1634.
18. Uzaraga I, Gerbis B, Holwerda E, et al. Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: A pilot study. Support Care Cancer. 2012;20(7):1515-1524.
19. Yosipovitch G, Maibach HI. Effect of topical pramoxine on experimentally induced pruritus in humans. J Am Acad Dermatol. 1997;37(2 Pt 1):278-280.
20. Zeidler C, Luling H, Dieckhofer A, et al. Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus? Br J Dermatol. 2015;172(6):1669-1671.
21. Yosipovitch G, Maibach HI, Rowbotham MC. Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia. Acta Derm Venereol. 1999;79(2):118-121.
22. Gibson RA, Robertson J, Mistry H, et al. A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers. PLoS One. 2014;9(7): e100610.
23. Moustafa F, Feldman SR. A review of phosphodiesterase inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20(5):22608.
24. Anacor pharmaceuticals announces positive results from phase 2 dose-ranging study of AN2728 in adolescents with atopic dermatitis (NASDAQ:ANAC) [Internet]; [cited 2015 Sep 14]. Available from: http://investor.anacor.com/releasedetail.cfm?releaseid=750026.
25. Clinicaltrials.gov. Safety and efficacy of AN2728 topical ointment, 2% in children, adolescents, and adults (aged 2 years and older) with atopic dermatitis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02118792?term=an2728&rank=3
26. Zhai H, Hannon W, Hahn GS, et al. Strontium nitrate decreased histamine-induced itch magnitude and duration in man. Dermatology. 2000;200(3):244-246.
27. Papoiu AD, Valdes-Rodriguez R, Nattkemper LA, et al. A novel topical formulation containing strontium chloride significantly reduces the intensity and duration of cowhage-induced itch. Acta Derm Venereol. 2013;93(5):520-526.
28. Yamaguchi J, Aihara M, Kobayashi Y, et al. Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis. J Dermatol Sci. 2009;53 (1):48-54.
29. Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542-548.
30. Senba E, Katanosaka K, Yajima H, et al. The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res. 2004;50(3):257-262.
31. Zhu Y, Pan WH, Wang XR, et al. Tryptase and proteaseactivated receptor-2 stimulate scratching behavior in a murine model of ovalbumin-induced atopic-like dermatitis. Int Immunopharmacol. 2015;28(1):507-512.
32. Ring J, Mohrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 2008;31(3):185-198.
33. Van Leent EJ, Ebelin ME, Burtin P, et al. Low systemic exposure after repeated topical application of pimecrolimus (elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology. 2002;204(1):63-68.
34. Margolis DJ, Abuabara K, Hoffstad OJ, et al. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015;151(6):594-599.
35. Sugimoto M, Arai I, Futaki N, et al. COX-1 inhibition enhances scratching behaviour in NC/nga mice with atopic dermatitis. Exp Dermatol. 2006;15(8):582-588.
36. Inoue T, Sugimoto M, Sakurai T, et al. Modulation of scratching behavior by silencing an endogenous cyclooxygenase-1 gene in the skin through the administration of siRNA. J Gene Med. 2007;9(11):994-1001.
37. Stander S, Schmelz M, Metze D, et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci. 2005;38(3):177-188.
38. Toth BI, Szallasi A, Biro T. Transient receptor potential channels and itch: how deep should we scratch? Handb Exp Pharmacol. 2015;226:89-133.
39. van der Stelt M, Trevisani M, Vellani V, et al. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. Embo J. 2005;24(17):3026-3037.
40. Stander S, Reinhardt HW, Luger TA. Topical cannabinoid agonists: an effective new possibility for treating chronic pruritus. Hautarzt. 2006;57(9):801-807.
41. Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat. 2005;13(2):97-103.
42. Sur R, Nigam A, Grote D, et al. Avenanthramides, polyphenols from oats, exhibit anti-inflammatory and antiitch activity. Arch Dermatol Res. 2008;300(10):569-574.
43. Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch. Handb Exp Pharmacol. 2015;226:337-356.
44. Zhai H, Frisch S, Pelosi A, et al. Antipruritic and thermal sensation effects of hydrocortisone creams in human skin. Skin Pharmacol Appl Skin Physiol. 2000;13(6):352-357.
45. Wilson SR, Gerhold KA, Bifolck-Fisher A, et al. TRPA1 is required for histamine-independent, mas-related G protein-coupled receptor-mediated itch. Nat Neurosci. 2011;14(5):595-602.
46. Chen J, Hackos DH. TRPA1 as a drug target-promise and challenges. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(4):451-463.
47. Denda M, Tsutsumi M. Roles of transient receptor potential proteins (TRPs) in epidermal keratinocytes. Adv Exp Med Biol. 2011;704:847-860.
48. Yamamoto-Kasai E, Imura K, Yasui K, et al. TRPV3 as a therapeutic target for itch. J Invest Dermatol. 2012;132 (8):2109-2112.
49. Wilson SR, Bautista DM. Role of transient receptor potential channels in acute and chronic itch. In: Carstens E, Akiyama T, editors. Itch: mechanisms and treatment. Boca Raton (FL): Taylor & Francis Group, LLC; 2014.
50. Wallengren J. Topical aprepitant in clinical and experimental pruritus. Arch Dermatol. 2012;148(8):957-959.
51. Liu Q, Weng HJ, Patel KN, et al. The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci Signal. 2011;4(181):ra45.
52. Reddy VB, Iuga AO, Shimada SG, et al. Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. J Neurosci. 2008;28 (17):4331-4335.
53. Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: A novel pathway for pruritus in human skin. J Neurosci. 2003;23(15):6176-6180.
54. Reddy VB, Sun S, Azimi E, et al. Redefining the concept of protease-activated receptors: cathepsin S evokes itch via activation of mrgprs. Nat Commun. 2015;6:7864.
55. Kim N, Bae KB, Kim MO, et al. Overexpression of cathepsin S induces chronic atopic dermatitis in mice. J Invest Dermatol. 2012;132(4):1169-1176.
56. Schonefuss A, Wendt W, Schattling B, et al. Upregulation of cathepsin S in psoriatic keratinocytes. Exp Dermatol. 2010;19(8):e80-8.
57. Stander S, Weisshaar E, Raap U. Emerging drugs for the treatment of pruritus. Expert Opin Emerg Drugs. 2015;20 (3):515-521.
58. Mansour-Ghanaei F, Taheri A, Froutan H, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol. 2006;12(7):1125-1128.
59. Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet. 1996;348 (9041):1552-1554.
60. Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006;54 (3):527-531.
61. Inui S. Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol. 2015;8:249-255.
62. Ehrchen J, Stander S. Pregabalin in the treatment of chronic pruritus. J Am Acad Dermatol. 2008;58(2 Suppl): S36-7.
63. Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant. 2004;19(12):3137-3139.
64. Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol. 2004;50(6):889-891.
65. Stander S, Bockenholt B, Schurmeyer-Horst F, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol. 2009;89(1):45-51.
66. Mayo MJ, Handem I, Saldana S, et al. Sertraline as a firstline treatment for cholestatic pruritus. Hepatology. 2007;45(3):666-674.
67. Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med. 2009;361(14):1415-1416.
68. Stander S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968.
69. Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429-438.
70. Maley A, Swerlick RA. Azathioprine treatment of intractable pruritus: a retrospective review. J Am Acad Dermatol. 2015;73(3):439-443.
71. Haeck IM, Knol MJ, Ten Berge O, et al. Enteric-coated mycophenolate sodium versus cyclosporin A as longterm treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol. 2011;64(6):1074-1084.
72. Kanwar AJ, De D. Methotrexate for treatment of lichen planus: Old drug, new indication. J Eur Acad Dermatol Venereol. 2013;27(3):e410-3.
73. Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virusinfected subjects: efficacy and risk of neuropathy. Arch Dermatol. 2004;140(7):845-849.
74. Kanavy H, Bahner J, Korman NJ. Treatment of refractory prurigo nodularis with lenalidomide. Arch Dermatol. 2012;148(7):794-796.
75. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.
76. Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73 (3):400-409.
77. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101-109.
78. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015 Sep 10. [Epub ahead of print].
79. Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol. 2000;11(3):514-519.
80. Jung SI, Seo CH, Jang K, et al. Efficacy of naltrexone in the treatment of chronic refractory itching in burn patients: preliminary report of an open trial. J Burn Care Res. 2009;30(2):257,60. discussion 261
81. Cowan A, Yosipovitch G. Preface. Handb Exp Pharmacol. 2015;226:v-vi.
82. Cara therapeutics announces positive results from phase 2 trial in uremic pruritus (NASDAQ:CARA) [Internet]; [cited 2015 Sep 14]. Available from: http://ir.caratherapeu tics.com/releasedetail.cfm?releaseid=923457.
83. Papoiu AD, Kraft RA, Coghill RC, et al. Butorphanol suppression of histamine itch is mediated by nucleus accumbens and septal nuclei: a pharmacological fMRI study. J Invest Dermatol. 2015;135(2):560-568.
84. Liao CC, Chang CS, Tseng CH, et al. Efficacy of intramuscular nalbuphine versus diphenhydramine for the prevention of epidural morphine-induced pruritus after cesarean delivery. Chang Gung Med J. 2011;34(2):172-178.
85. Clinicaltrials.gov. Study of nalbuphine HCL ER tablets in hemodialysis patients with uremic pruritus [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinical trials.gov/ct2/show/NCT02143648?term=nalbuphine +pruritus&rank=1.
86. Clinicaltrials.gov study of nalbuphine HCL ER tablets in patients with prurigo nodularis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02174419?term=nalbuphine+pruritus& rank=5
87. Tioga pharmaceuticals announces initiation of phase 2 clinical study of asimadoline in⋯ - SAN DIEGO, June 11, 2015 /PRNewswire/- [Internet]; [cited 2015 Sep 22]. Available from: http://www.prnewswire.com/newsreleases/tioga-pharmaceuticals-announces-initiation-ofphase-2-clinical-study-of-asimadoline-in-patients-withpruritus-associated-with-atopic-dermatitis-300097588.html
88. Roberson DP, Gudes S, Sprague JM, et al. Activity-dependent silencing reveals functionally distinct itch-generating sensory neurons. Nat Neurosci. 2013;16(7):910-918.
89. Ikoma A, Steinhoff M, Stander S, et al. The neurobiology of itch. Nat Rev Neurosci. 2006;7(7):535-547.
90. Davis MP, Frandsen JL, Walsh D, et al. Mirtazapine for pruritus. J Pain Symptom Manage. 2003;25(3):288-291.
91. Lee JJ, Girouard SD, Carlberg VM, et al. Effective use of mirtazapine for refractory pruritus associated with carcinoma en cuirasse. BMJ Support Palliat Care. 2014 Dec 16. [Epub ahead of print].
92. Namaka M, Gramlich CR, Ruhlen D, et al. A treatment algorithm for neuropathic pain. Clin Ther. 2004;26 (7):951-979.
93. Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;55(3):543-544.
94. Stander S, Luger TA. NK-1 antagonists and itch. Handb Exp Pharmacol. 2015;226:237-255.
95. Clinicaltrials.gov. Effect of neurokinin-1 receptor (NK1R) antagonism on pruritus in patients with sezary syndrome [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01625455?term=apre pitant+sezary&rank=1
96. Press release | tigercat | chronic pruritus [Internet]; [cited 2015 Sep 14]. Available from: http://tonydimatteo.com/tigercat/category/press-release/.
97. Clinicaltrials.gov. A randomized placebo-controlled study of the neurokinin-1 (NK1) receptor antagonist VPD-737 prurigo nodularis (PN) [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02196324?term=serlopitant&rank=1
98. Vanda pharmaceuticals announces tradipitant phase II proof of concept study results for chronic⋯ - WASHINGTON, march 4, 2015 /PRNewswire/- [Internet]; [cited 2015 Sep 14]. Available from: http://www.prnews wire.com/news-releases/vanda-pharmaceuticalsannounces-tradipitant-phase-ii-proof-of-concept-studyresults-for-chronic-pruritus-in-atopic-dermatitis-300045700.html.
99. Pacor ML, Di Lorenzo G, Martinelli N, et al. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin Exp Allergy. 2004;34(4):639-645.
100. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142(1):52-58.
101. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebocontrolled, crossover trial. Br J Dermatol. 2002;147 (2):324-330.
102. Neuber K, Schwartz I, Itschert G, et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol. 2000;143(2):385-391.
103. Ballester I, Silvestre JF, Perez-Crespo M, et al. Severe adult atopic dermatitis: treatment with mycophenolate mofetil in 8 patients. Actas Dermosifiliogr. 2009;100(10):883-887.
104. Zimmerman AB, Berger EM, Elmariah SB, et al. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients. J Am Acad Dermatol. 2012;66(5):767-770.
105. Daly BM, Shuster S. Antipruritic action of thalidomide. Acta Derm Venereol. 2000;80(1):24-25.
106. Ladizinski B, Shannon EJ, Sanchez MR, et al. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. J Drugs Dermatol. 2010;9(7):814-826.
107. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868-887.
108. O'Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther. 2005;18(4):333-340.
109. Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-139.
110. Clinicaltrials.gov. A study of lebrikizumab in patients with persistent moderate to severe atopic dermatitis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02340234?term= lebrikizumab&rank=3
111. Raap U, Wichmann K, Bruder M, et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol. 2008;122(2):421-423.
112. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411-417.
113. Cedeno-Laurent F, Singer EM, Wysocka M, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015;158(1):1-7.
114. Grimstad O, Sawanobori Y, Vestergaard C, et al. Antiinterleukin-31-antibodies ameliorate scratching behaviour in NC/nga mice: a model of atopic dermatitis. Exp Dermatol. 2009;18(1):35-43.
115. Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized anti-human IL-31 receptor A antibody, for healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomised, double-blind, placebo-controlled study. Br J Dermatol. 2015 Sep 26. [Epub ahead of print].
116. Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319-324.
117. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-tosevere psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386 (9993):541-551.
118. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135 (2):324-336.
119. Puya R, Alvarez-Lopez M, Velez A, et al. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol. 2012;51(1):115-116.
120. Clinicaltrials.gov. A study of ustekinumab in adult japanese participants with severe atopic dermatitis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01945086?term=ustekinumab +atopic+dermatitis&rank=1
121. Kim DH, Park KY, Kim BJ, et al. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38(5):496-500.
122. Montes-Torres A, Llamas-Velasco M, Perez-Plaza A, et al. Biological treatments in atopic dermatitis. J Clin Med. 2015;4(4):593-613.
123. Clinicaltrials.gov. Role of anti-IgE in severe childhood eczema (ADAPT) [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02300701?term=omalizumab+atopic+dermatitis& rank=4
124. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37-49.
125. Samrao A, Berry TM, Goreshi R, et al. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148 (8):890-897.
126. Mamolo CM, Bushmakin AG, Cappelleri JC. Application of the itch severity score in patients with moderate-tosevere plaque psoriasis: clinically important difference and responder analyses. J Dermatolog Treat. 2015;26 (2):121-123.
127. Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137-145.
128. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73(3):395-399.
129. Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274-283.
130. Weinfeld PK. Successful treatment of notalgia paresthetica with botulinum toxin type A. Arch Dermatol. 2007;143(8):980-982.
131. Wessler I, Reinheimer T, Kilbinger H, et al. Increased acetylcholine levels in skin biopsies of patients with atopic dermatitis. Life Sci. 2003;72(18-19):2169-2172.
132. Heyer G, Vogelgsang M, Hornstein OP. Acetylcholine is an inducer of itching in patients with atopic eczema. J Dermatol. 1997;24(10):621-625.
133. Heckmann M, Heyer G, Brunner B, et al. Botulinum toxin type A injection in the treatment of lichen simplex: an open pilot study. J Am Acad Dermatol. 2002;46(4):617-619.
134. Gazerani P, Pedersen NS, Drewes AM, et al. Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. Br J Dermatol. 2009;161(4):737-745.
135. Mishra SK, Hoon MA. Transmission of pruriceptive signals. Handb Exp Pharmacol. 2015;226:151-162.
136. Sukhtankar DD, Ko MC. Physiological function of gastrinreleasing peptide and neuromedin B receptors in regulating itch scratching behavior in the spinal cord of mice. PLoS One. 2013;8(6):e67422.
137. Mishra SK, Hoon MA. The cells and circuitry for itch responses in mice. Science. 2013;340(6135):968-971.
138. Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344-1354.
139. Clinicaltrials.gov. Randomized placebo controlled study to determine safety, pharmacodynamics and efficacy of ILV-094 in atoipc dermatitis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT01941537?term=NCT01941537&rank=1
140. Wilson SR, The L, Batia LM, et al. The epithelial cellderived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013;155(2):285-295.
141. Lee EB, Kim KW, Hong JY, et al. Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. Pediatr Allergy Immunol. 2010;21(2 Pt 2):e457-60.
142. Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3 (7):673-680.
143. Safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT00757042?term=amg157+atopic+dermatitis&rank=1
144. Kremer AE, Bolier R, van Dijk R, et al. Advances in pathogenesis and management of pruritus in cholestasis. Dig Dis. 2014;32(5):637-645.
145. Kremer AE, van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;56(4):1391-1400.
146. Clinical trials.gov. IBAT inhibitor A2450 for cholestatic pruritus [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02360852? term=a4250&rank=1